These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24803795)

  • 21. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review.
    Filippi J; Allen PB; Hébuterne X; Peyrin-Biroulet L
    Curr Drug Targets; 2011 Sep; 12(10):1440-7. PubMed ID: 21466486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.
    Nelson R; Liao C; Fichera A; Rubin DT; Pekow J
    Inflamm Bowel Dis; 2014 Jan; 20(1):14-20. PubMed ID: 24297054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
    Lawson MM; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
    Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
    Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.
    Murthy SK; Greenberg GR; Croitoru K; Nguyen GC; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2015 Sep; 21(9):2090-6. PubMed ID: 26099066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis.
    Löwenberg M; Duijvis NW; Ponsioen C; van den Brink GR; Fockens P; D'Haens GR
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1240-6. PubMed ID: 25171024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis.
    Jia X; Guo R; Hu Z; Liu J; Liu J; Li B; Yang Q; He J
    Medicine (Baltimore); 2020 Oct; 99(44):e22894. PubMed ID: 33126341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.
    Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1301-9. PubMed ID: 22506582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study.
    Nasuno M; Miyakawa M; Tanaka H; Motoya S
    Digestion; 2017; 95(1):67-71. PubMed ID: 28052276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
    Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis.
    Zhao HN; Jiang M; Sun MJ; Dai C
    Saudi J Gastroenterol; 2021; 27(4):191-200. PubMed ID: 34380865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.
    Yamada S; Yoshino T; Matsuura M; Minami N; Toyonaga T; Honzawa Y; Tsuji Y; Nakase H
    BMC Gastroenterol; 2014 Apr; 14():80. PubMed ID: 24758588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients.
    Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience.
    Teisner AS; Ainsworth MA; Brynskov J
    Scand J Gastroenterol; 2010 Dec; 45(12):1457-63. PubMed ID: 20701434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis.
    Lofland JH; Mallow P; Rizzo J
    J Med Econ; 2013; 16(4):461-7. PubMed ID: 23445401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
    Martelli L; Olivera P; Roblin X; Attar A; Peyrin-Biroulet L
    J Gastroenterol; 2017 Jan; 52(1):19-25. PubMed ID: 27665099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
    Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
    Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.